Clinical Trial Update: Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients [NA]

View source ↗

Summary

A completed clinical trial evaluating MF4637 for correcting omega-3 nutritional deficiency in non-alcoholic fatty liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• MF4637 (MF4637)

Snippet

Sponsor: Pronova BioPharma | Conditions: Non Alcoholic Fatty Liver | NA | Status: COMPLETED